Empowering the Future of Tech-Driven Healthcare
LiHe NeoSyn BioMeridian Technology Inc serves as the strategic, analytical, and regulatory hub for our parent company's North American expansion. Operating at the intersection of advanced healthcare consulting and professional data services, we bridge innovative therapeutic principles with Western clinical standards.
Core Business Pillars
Regulatory Affairs and FDA Liaison
As the primary contact for North American operations, we drive strategic alignment and cross-border data bridgeheads to navigate the FDA regulatory pathway.
- Regulatory Strategy & Compliance Monitoring
- Clinical Data Bridge & Submission Support
Advanced Data Analytics and Technology Support
Our team transforms complex clinical and market data into actionable business intelligence through sophisticated modeling and post-market tech infrastructure.
- Intelligent Data Modeling & Treatment Efficacy Analysis
- Pre-Market Insights & Demographic Usage Patterns
Cross-Border Compliance and Data Governance
Navigating international data flows is a cornerstone of our consulting expertise, ensuring absolute security and legal compliance.
- Secure China-U.S. Clinical Data Transfer Consulting
- Strict Adherence to HIPAA & Global Privacy Frameworks
Our Parent Company
Henan Lixinghe Medical Technology Co., Ltd.
"Lixinghe" was established on August 10, 2021, in Henan, China. It is a premier, nationally recognized high-tech enterprise dedicated to the research, development, and manufacturing of advanced medical modalities. Certified as a "Specialized and Sophisticated" corporate leader, Lixinghe maintains a prestigious AAA corporate credit rating and a fully compliant Intellectual Property Management System. As the pioneering parent institution, Lixinghe provides the foundational technology and strategic backing to drive the global modernization of tech-driven healthcare.
Built at the intersection of Traditional Chinese Medicine and Technology
Lixinghe's proprietary technology represents a major breakthrough, born from a strategic collaboration between leading radiowave propagation experts and seasoned clinical specialists. By transitioning medical development "from bench to bedside," the company pioneered a non-contact and non-invasive treatment modality that utilizes advanced non-contact focused radiators to deliver specific-frequency microwave energy precisely to human acupoints, simulating and enhancing the therapeutic physiological resonance traditionally sought in standard acupuncture.
Core Technological Advantages
Advantage 01
Meridian-Informed Framework
Its conceptual foundation draws from Traditional Chinese Medicine, where acupoints and meridian pathways inform stimulation strategy and device positioning.
Advantage 02
Non-Invasive Design
The platform is designed around external acupoint stimulation rather than penetrating instrumentation, supporting a more controlled and operator-guided experience.
Advantage 03
Standardized Operation
Modern controls, display guidance, and equipment design help standardize how the platform is presented, studied, and discussed.
Advantage 04
Precise Positioning
A ten-dimensional probe matrix combined with an AI positioning algorithm reduces energy focus error to less than 0.5 mm, enabling highly accurate target localization.
Advantage 05
Deep Penetration
2.45GHz adaptive frequency conversion waveguide technology achieves an effective penetration depth of 8.2 cm, reaching deep-seated lesions that traditional acupuncture devices (limited to <3 cm) cannot access.
Advantage 06
Intelligent Temperature Control
A distributed PID temperature control module maintains a constant 42°C ±0.3°C, overcoming microwave energy attenuation to improve thermal therapy efficiency by 50% while ensuring treatment safety.
Microwave Acupuncture Therapeutic Apparatus
This breakthrough achieved the world's first successful application of this technological pathway in Class III medical devices. It led to the development of our flagship Microwave Acupuncture Therapeutic Apparatus, marketed under the brands Yijingdao and Duoweidao. We also developed an approved portfolio of Class II systems and obtained manufacturing licenses. Guided by the future of digital healthcare, Lixinghe is actively integrating Medical + AI. Following the completion of its neural network architecture, the company's proprietary healthcare large model entered its deep learning phase in 2026. It is designed to deliver expert-level, intelligent clinical decision support for standardized and personalized patient care.
Robust Global Intellectual Property Portfolio
To safeguard its paradigm-shifting innovations and pave the way for seamless international market entry, Lixinghe has established a robust global intellectual property portfolio. The company's domestic Chinese footprint includes 7 invention patents (covering Hong Kong, Macau, and Taiwan), 32 design and utility model patents, 65 registered or pending trademarks, and 3 software copyrights.
On the global stage, leveraging the Patent Cooperation Treaty (PCT) framework, Lixinghe has been granted formal patent protections in nearly 50 countries and territories—including critical regulatory environments such as the United States, Japan, South Korea, South Africa, Eurasia, and European Patent Office (EPO) member states like Germany, France, the UK, and Italy. With pending applications advancing in major global markets such as Canada and Brazil, Lixinghe's international IP footprint is projected to exceed 45 countries, ensuring absolute regulatory compliance and legal protection for its cutting-edge therapies worldwide.
Driving Innovation Through Local Partnerships
We advance the scientific frontiers of BioMeridian Technology by building strong intellectual foundations and cultivating strategic collaborations across the United States.
01
We partner with premier U.S. research centers and medical institutions to foster continuous clinical innovation.
02
We facilitate and oversee local clinical applications to validate the "Yi Jing Dao" system within Western medical frameworks.
03
We coordinate international standard-setting and manage intellectual property rights for proprietary technologies.
LiHe NeoSyn BioMeridian Technology Inc operates exclusively as a professional consulting, research-coordination, and data-driven office. We do not engage in local manufacturing, hardware production, or direct retail sales within the United States. Our focus remains entirely on the intellectual, analytical, and strategic foundations of our specialized medical technology.